Progestin treatment for the prevention of preterm birth

Acta Obstetricia et Gynecologica Scandinavica

Volumn 90, Issue 10, 2011, Pages 1057-1069

  Lucovnik, Miha ^a,b   Kuon, Ruben J ^a,c   Chambliss, Linda R ^a   Maner, William L ^a   Shi, Shao Qing ^a   Shi, Leili ^a   Balducci, James ^a   Garfield, Robert E ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

17 hydroxyprogesterone acetate; administration; pregnancy; Preterm birth; preterm labor; progesterone

Indexed keywords

GESTAGEN; HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE; UTERUS SPASMOLYTIC AGENT;

CHILDBIRTH; DRUG MECHANISM; FATIGUE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTRAHEPATIC CHOLESTASIS; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SOMNOLENCE; TWIN PREGNANCY; UTERUS CONTRACTION;

ADMINISTRATION, INTRAVAGINAL; CERVICAL RIPENING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE BIRTH; PRIMARY PREVENTION; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052973875     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01178.x     Document Type: Review

References (78)

1. Guyer B, MacDorman MF, Martin JA, Peters KD, Strobino DM,. Annual summary of vital statistics-1997. Pediatrics. 1998; 102: 1333-49.
2. Marlow N, Wolke D, Bracewell MA, Samara M, EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med. 2005; 352: 9-19. (Pubitemid 40075676)
3. Slattery MM, Morison JJ,. Preterm delivery. Lancet. 2002; 360: 1489-97. (Pubitemid 35356329)
4. Steer M,. The epidemiology of preterm labor. BJOG. 2005; 122 (Suppl 1): 1-3.
5. Muglia LJ, Katz M,. The enigma of spontaneous preterm birth. N Engl J Med. 2010; 362: 529-35.
6. Towers CV, Bonebrake R, Padilla G, Rumney P,. The effect of transport on the rate of severe intraventricular hemorrhage in very low birth weight infants. Obstet Gynecol. 2000; 95: 291-5. (Pubitemid 30045656)
7. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A,. Tocolytics for preterm labor: a systematic review. Obstet Gynecol. 1999; 94: 869-77. (Pubitemid 29490928)
8. Caritis SN, Edelstone DI, Mueller-Heubach E,. Pharmacologic inhibition of preterm labor. Am J Obstet Gynecol. 1997; 133: 557-78.
9. Garfield RE, Saade G, Buhimschi C, Buhimschi I, Shi L, Shi SQ, et al,. Control and assessment of the uterus and cervix during pregnancy and labour. Hum Reprod Update. 1998; 4: 673-95. (Pubitemid 29041481)
10. Lemancewivicz A, Laudanska H, Laudanski T, Karpiuk A, Batra S,. Permeability of fetal membranes to calcium and magnesium: possible role in preterm labour. Hum Reprod. 2000; 15: 2018-22.
11. Mizuki J, Tasaka K, Masumoto N, Kasahara K, Miyake A, Tanizawa O,. Magnesium sulfate inhibits oxytocin-induced calcium mobilization in human puerperal myometrial cells: possible involvement of intracellular free magnesium concentration. Am J Obstet Gynecol. 1993; 169: 134-9. (Pubitemid 23223944)
12. Ledingham MA, Thomson AJ, Greer IA, Norman JE,. Nitric oxide in parturition. BJOG. 2000; 107: 581-93. (Pubitemid 30242849)
13. Wray S, Jones K, Kupittayanant S, Li Y, Matthew A, Monir-Bisthy E, et al,. Calcium signaling and uterine contractility. J Soc Gynecol Investig. 2003; 10: 252-64. (Pubitemid 36802326)
14. Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA, et al,. Prostaglandins and mechanisms of preterm birth. Reproduction. 2002; 124: 1-17. (Pubitemid 34790216)
15. Phaneuf S, Asbõth G, MacKenzie IZ, Melin P, Lõpez Bernal A,. Effect of oxytocin antagonist on the activation of human myometrium in vivo: atosiban prevents oxytocin-induced desensitization. Am J Obstet Gynecol. 1994; 171: 1627-34.
16. Allen WM, Corner GW,. Physiology of the corpus luteum. VII. Maintenance of pregnancy in rabbit after very early castration by corpus luteum extracts. Proc Soc Exp Biol Med. 1930; 27: 403.
17. Csapo IA,. Progesterone "block". Am J Anat. 1956; 98: 273-92.
18. Mesiano S,. Myometrial progesterone responsiveness and the control of human parturition. J Soc Gynecol Investig. 2004; 11: 193-202. (Pubitemid 38561362)
19. Merlino AA, Welsh TN, Tan H, Yi LJ, Cannon V, Mercer BM, et al,. Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A. J Clin Endocrinol Metab. 2007; 92: 1927-33. (Pubitemid 46997211)
20. Sabeur K, Edwards DP, Meizel S,. Human sperm plasma membrane progesterone receptor(s) and the acrosome reaction. Biol Reprod. 1996; 54: 993-1001. (Pubitemid 26127847)
21. Wu W, Dong Y-L, Balducci J, Huang H, Garfield RE,. Expression of PGRMC1, a novel progesterone receptor component in human myometrium, is down regulated during labor at term and preterm. 57th Annual Scientific Meeting of the Society for Gynecologic Investigation; March 2010, Orlando, FL, # 320.
22. Chwalisz K,. The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery. Hum Reprod. 1994; 9 (Suppl 1): 131-61. (Pubitemid 24203937)
23. Xu H, Gonzalez JM, Ofori E, Elovitz MA,. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? Am J Obstet Gynecol. 2008; 198: 314.e1-8.
24. Kelly RW,. Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response. Endocr Rev. 1994; 15: 684-706.
25. Kuon RJ, Shi S-Q, Maul H, Sohn C, Balducci J, Maner WL, et al,. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol. 2010; 202: 455.e1-9.
26. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A,. Cervical length changes during preterm cervical ripening: effects of 17-α- hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007; 196: 453.e1-4.
27. O'Brien JM, DeFranco EA, Adair CD, Lewis DF, Halls DR, How H, et al,. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2009; 34: 653-9.
28. Shi SQ, Maner WL, Mackay LB, Garfield RE,. Identification of term and preterm labor in rats using artificial neural networks on uterine electromyography signals. Am J Obstet Gynecol. 2008; 198: 235.e1-4.
29. Ruddock N, Shi S-Q, Jain S, Moore G, Hankins GDV, Romero R, et al,. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008; 199: 391.e1-7.
30. Sexton DJ, O'Reilly MW, Friel AM, Morrison JJ,. Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol. 2004; 2: 80.
31. Mitchell BF, Taggart MJ,. Are animal models relevant to key aspects of human parturition? Am J Physiol Regul Integr Comp Physiol. 2009; 297: R525-45.
32. Tulchinsky D, Hobel CY, Yeager E, Marshall YR,. Plasma estrone, estradiol, estriol, progesterone, and 17α-hydroxyprogesterone in human pregnancy. I. Normal pregnancy. Am J Obstet Gynecol. 1972; 112: 1095-100.
33. Zarrow MX, Anderson NC, Callantine MR,. Failure of progesterone to prolong pregnancy in guinea pig. Nature. 1963; 198: 690-2.
34. Porter DG,. The failure of progesterone to affect myometrial activity in guinea-pig. J Endocr. 1970; 46: 425-34.
35. Fuchs F, Stakemann G,. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol. 1960; 79: 172-6.
36. Hobel CJ, Ross MG, Bemis RL, Bragonier JR, Nessim S, Sandhu S, et al,. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high risk women. Am J Obstet Gynecol. 1994; 170: 54-62. (Pubitemid 24084031)
37. Neilson JP,. Mifepristone for induction of labor. Cochrane Database Syst Rev. 2000;(4): CD002865.
38. Thong KJ, Baird DT,. Induction of abortion with mifepristone and misoprostol in early pregnancy. BJOG. 2005; 99: 1004-7.
39. Mitchell BF, Mitchell JM, Chowdhury J, Tougas M, Engelen SM, Senff M, et al,. Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? Am J Obstet Gynecol. 2005; 192: 1304-13.
40. Condon JC, Hardy DB, Kovaric K, Mandelson CR,. Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol. 2005; 20: 764-75.
41. Rode L, Langhoff-Roos J, Andersson C, Dinesen J, Schou Hammerun M, Mohapeloa H, et al,. Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand. 2009; 88: 1180-9.
42. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M,. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003; 188: 419-24. (Pubitemid 36249980)
43. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH,. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007; 357: 462-9. (Pubitemid 47204875)
44. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al,. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007; 30: 687-96. (Pubitemid 47612689)
45. Murray JL,. Natural progesterone: what role in women's health care? Women's Health Primary Care. 1998; 1: 671-87.
46. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, et al,. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol. 2007; 110: 865-72. (Pubitemid 47508752)
47. Onsrud M, Paus E, Haug E, Kjørstad K,. Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacocinetics and effects on adrenal function. Acta Obstet Gynecol Scand. 1985; 64: 519-23. (Pubitemid 15241030)
48. Ness A, Dias T, Damus K, Burd I, Bergella V,. Impact of the recent randomized trial on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol. 2005; 195: 1174-9. (Pubitemid 44415661)
49. Gibbons WE, Toner JP, Hamacher P, Kolm P,. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998; 69: 96-101. (Pubitemid 28073000)
50. Tavaniotou A, Smitz J, Bourgain C, Devroey P,. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000; 6: 139-48. (Pubitemid 30182295)
51. Seegmiller RE, Nelson GW, Johnson CK,. Evaluation of the teratogenic potential of Delalutin (17alpha-hydroxyprogesterone caproate) in mice. Teratology. 1983; 28: 201-8. (Pubitemid 14227781)
52. Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, et al,. Embriotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate. Teratology. 1987; 35: 129-36. (Pubitemid 17029327)
53. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al,. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348: 2379-85. (Pubitemid 36682816)
54. Keirse MJNC,. Progestogen administration in pregnancy may prevent preterm delivery. BJOG. 1990; 97: 149-54. (Pubitemid 20134285)
55. Brancazio LR, Murtha AP, Heine RP,. Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 349: 1987-8.
56. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al,. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 1986; 154: 525-9. (Pubitemid 16128013)
57. Noblot G, Audra P, Dargent D, Faguer B, Mellier G,. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 1991; 40: 203-9.
58. Rai P, Rajaram S, Goel N, Gopalakrishnan RA, Agarwal R, Mehta S,. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009; 104: 40-3.
59. De Ziegler D, Bulletti C, De Monstier B, Jaaskelainen A-S,. The first pass uterine effect. Ann N Y Acad Sci. 1997; 828: 291-9.
60. Cicinelli E, Cignarelli M, Sabatelli S, Romano F, Schonauer LM, Padovano R, et al,. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril. 1998; 69: 471-3.
61. Richardson JL, Illum L,. The vaginal route of peptide and protein drug delivery. Adv Drug Deliv Rev. 1992; 8: 341-366.
62. Borna S, Sahabi N,. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynecol. 2008; 48: 58-63. (Pubitemid 351239131)
63. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al,. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomized, double-blind, placebo-controlled study and meta-analysis. Lancet. 2009; 373: 2034-40.
64. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter J, Khandelwal M, et al., Vaginal progesterone reduces the rate of preterm birth in woman with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011; epub ahead of print.
65. Papiernik-Berkhauer E,. Etude en double aveugle d'un medicament prenvenant la survenue premature de l'accouchement chez les femmes a risqué d'accouchement premature [Double blind study of a drug to prevent the occurence of preterm delivery in women at high risk. Edition Shering Serie IV. 1970; 3: 65-8.
66. Johnson JW, Lee PA, Zachary AS, Calhoun S, Migeon CJ,. High-risk prematurity-progestin treatment and steroid studies. Obstet Gynecol. 1979; 54: 412-8. (Pubitemid 9247464)
67. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al,. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985; 151: 574-7. (Pubitemid 15049683)
68. Hartikainen-Sorri A-L, Kauppila A, Tuimala R,. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Am J Obstet Gynecol. 1980; 56: 692-5. (Pubitemid 11216937)
69. Hauth JC, Gilstrap LC III, Brekken AL, Hauth JM,. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 1983; 146: 187-90. (Pubitemid 13092766)
70. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al,. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005; 105: 267-72. (Pubitemid 40229440)
71. Greene MF,. Progesterone and preterm delivery - déjà vu all over again. N Engl J Med. 2003; 348: 2453-5. (Pubitemid 36682825)
72. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al,. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007; 357: 454-61. (Pubitemid 47204874)
73. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al,. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007; 30: 697-705. (Pubitemid 47612690)
74. Iams JD, Romero R,. Preterm birth. In:, Gabbe SG, Niebyl JR, Simpson JL, (eds). Obstetrics: normal and problem pregnancies. 5th edn. Philadelphia, PA: Churchill Livingstone Elsevier, 2007. pp. 668-712.
75. Kauppila A, Hartikainen-Sorri A-L, Janne O, Tuimala R, Jarvinen PA,. Suppression of threatened premature labor by administration of cortisol and 17α-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol. 1980; 138: 404-8. (Pubitemid 11226070)
76. Maner WL, Garfield RE, Maul H, Olson G, Saade G,. Predicting term and preterm delivery with transabdominal uterine electromyography. Obstet Gynecol. 2003; 101: 1254-60. (Pubitemid 36694352)
77. Lucovnik M, Maner WL, Chambliss LR, Blumrick R, Balducci J, Novak-Antolic Z, et al,. Noninvasive uterine electromyography for prediction of preterm delivery. Am J Obstet Gynecol. 2011; 204: 228.e1-10.
78. Lucovnik M, Kuon RJ, Chambliss LR, Maner WL, Shi S-Q, Shi L, et al,. Use of uterine electromyography to diagnose term and preterm labor. Acta Obstet Gynecol Scand. 2011; 90: 150-7.